The Research

This pilot study evaluated the safety and efficacy of combining oxymetazoline hydrochloride (OXY) with mometasone furoate (MNS) nasal spray in adults with a ≥1-year history of moderate-to-severe nasal congestion that was unresponsive to corticosteroid monotherapy. The 20-day, randomized, double-blind, placebo-controlled trial compared MNS + OXY versus MNS + placebo in 23 patients.

This randomized, double-blind, active-controlled, multicenter study evaluated a fixed-dose combination (FDC) of fluticasone furoate (27.5 mcg) and oxymetazoline hydrochloride (50 mcg) nasal spray, administered once nightly, in patients with moderate-to-severe allergic rhinitis and nasal congestion. The study compared the FDC to fluticasone monotherapy over 28 days, assessing symptom improvement and safety.